Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
More Reading from MarketBeat.com Battle of Healthcare Sector Earnings: AZN vs. EW vs. ZBHAuthor: Nathan Reiff. Article Posted: 2/10/2026. More than just a financial check-up, earnings for companies in the healthcare sector offer a key window for investors into a firm's pipeline and development progress. Even well-established, stable firms in the healthcare space can surprise with growth following the release of a new blockbuster drug or medical device, and earnings periods are an opportunity for management to provide insight beyond what investors might expect from FDA notices of approvals. When healthcare names report earnings on the same day, it can be a busy time for investors trying to sort the noteworthy news and plan trades. On Feb. 10, 2025, three major names in the sector—AstraZeneca (NASDAQ: AZN), Edwards Lifesciences (NYSE: EW), and Zimmer Biomet (NYSE: ZBH)—all reported full-year and Q4 2025 results. Below are highlights and takeaways for healthcare investors looking to form an informed plan based on these updates. AstraZeneca Firms Up Cancer Business In a Strong Overall Quarterly Performance U.K.-based pharma giant AstraZeneca ended 2025 by cementing its position as a leading provider of cancer medicines, which accounted for about 44% of product sales in the final quarter of the year. Sales of key oncology drugs such as Imfinzi and Enhertu grew as much as 48% year-over-year (YoY), helping to drive total revenue growth of 8.6% to $58.7 billion for the quarter. After-tax profits climbed to $10.2 billion from $7.0 billion in the prior-year quarter, and the board declared a second interim dividend seven cents higher than last year's. After signing more than 220 Executive Orders… more than any president in American history… Donald Trump is preparing for one final move.
On February 24th — I have every reason to believe he will sign his Final Executive Order.
When I say that it's his FINAL executive order… Click here or below for this unbelievable story… Investors will also have more to watch in the year ahead as the company advances dozens of drugs through clinical trials. Management indicated that 20 Phase 3 readouts are expected in 2026, and the firm forecasted solid increases to both total revenue and core earnings per share (EPS) for the full year. In the hours after its strong earnings release, AZN shares climbed nearly 3%. Despite the positive analyst sentiment—10 out of 11 analysts rate AZN a Buy or equivalent—the consensus price target of $95.75 implies roughly 51% downside from current levels, raising questions about valuation. Edwards Lifesciences: What to Watch Edwards Lifesciences, a leader in transcatheter heart valves and critical-care monitoring, also reported results on Feb. 10. Company commentary typically focuses on trends in procedure volumes (particularly TAVR), pricing dynamics, and margin trajectory—items that can be more meaningful to investors than headline revenue numbers alone. For Edwards, investors will be watching guidance for 2026, any updates on new product launches or regulatory milestones, and how the company expects procedure trends to normalize post-pandemic. See the company's full report and MarketBeat coverage for specific figures and management commentary. Orthopedic Demand Remains High, But Zimmer Faces Some Headwinds Going Forward Makers of joint replacement systems and implants, Zimmer Biomet saw its shares rise more than 3% hours after announcing adjusted EPS of $2.42 (four cents above consensus) and revenue of $2.2 billion, up nearly 11% YoY and slightly ahead of estimates. Strong demand for Zimmer's orthopedic products helped fuel both top- and bottom-line growth. Zimmer is also in the midst of a strategic shift that will focus the company more heavily on U.S. sales, which account for close to 60% of its business. As insured patients continue to increase utilization, near-term demand for Zimmer's products is expected to remain supportive. Still, Zimmer could face headwinds from tariffs and other trade-related costs that may pressure EPS and revenue in 2026. Management issued conservative guidance in the latest earnings report, including adjusted EPS between $8.30 and $8.45 and expected free cash flow improvement of 8% to 10%. Ahead of the release, analysts remain divided on Zimmer, and the company carries an overall Hold rating despite about 15% projected upside potential.
| 
